The company’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.


From the WSJ –>

Novavax Covid-19 Vaccine Is 90% Effective, Including Against Variants, New Study Shows

Authorization of the two-dose vaccine is months away, however, as Novavax readies manufacturing

“The vaccine also contains an adjuvant, a substance designed to enhance immune responses. Novavax’s adjuvant is derived from the bark of an evergreen tree native to Chile.

This approach of combining a protein with an adjuvant is similar to that of vaccines against other diseases, including GlaxoSmithKline GSK 0.20% PLC’s shingles vaccine, Shingrix.

It is a different mechanism from the Pfizer-BioNTech and Moderna Covid-19 vaccines, which use gene-based technologies, and those from Johnson & Johnson and AstraZeneca, AZN 0.14% which use viral-vector technology.”